Sanofi has been leading pharmaceutical innovation for over 100 years. Globally, the company has more than 100,000 employees in over 100 countries and is headquartered in Paris, France. Sanofi is organized into five global units, and their work in Norway is focused on four different therapeutic areas: primary care, consumer healthcare, specialty care, and vaccines. Sanofi-Aventis’ Norway branch is in Lysaker and employs 82 people.
Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies. For more than 130 years, the family-owned company has developed new medicines for people and animals. Boehringer Ingelheim’s nearly 50,000 employees work to implement the company’s mission to spread value through innovation in three core areas: human medicine, veterinary medicine, and biopharmaceutical contract-based production. The company demonstrates its social responsibility by actively participating in the “Making More Health” initiative and prioritizing environmental protection and sustainability in all levels of operation. In Norway, Boehringer Ingelheim employs 71 people. In 2018, Boehringer Ingelheim’s Norwegian Branch achieved a total net sales revenue of NOK 423,000,000.
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics, and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer’s disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, immunology, neurocognitive disorders, acute neurology, and pain.
GSK’s purpose is to help people do more, feel better, and live longer. As one of the world’s largest, research-based pharmaceutical companies, GSK employs 100,000 people in over 150 countries. GSK’s goal is to be one of the world’s most innovative, best performing, and trusted healthcare companies, and the company aims to bring differentiated, high-quality, and needed healthcare products to as many people as possible. GSK has three global businesses within innovative pharmaceutical medicines (with a focus on respiratory diseases and HIV), vaccines, and consumer healthcare products. The company’s R&D approach is related to the immune system, use of genetics, and advanced technologies. In Norway, GSK has 80 employees and a turnover of about NOK 700 million.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof has made Roche the leader in personalized healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology, and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.